The TSO 500 HRD research test aligns Myriad's gold standard MyChoice® CDx HRD technology with Illumina's pan-cancer test, TSO 500. The test was codeveloped with Merck (known as MSD outside the US and ...

Myriad Genetics, Inc. (NASDAQ: MYGN) today announced new clinical studies on its myChoice HRD companion diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in ...

Homologous recombination repair deficiency (HRD) is associated with response to poly-ADP-ribose polymerase inhibition (PARPi) therapy in advanced ovarian cancer. In combination with CGP, these ...

SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at ...

A community-based study found that despite current guidelines recommending that all patients diagnosed with epithelial ovarian cancer undergo testing for homologous repair deficiency (HRD), only about ...

Tesaro has made a deal with Myriad Genetics to use Myriad's homologous recombination deficiency (HRD) test to look for tumor types that may respond to its poly-ADP ribose polymerase (PARP) inhibitor, ...

The Association for Molecular Pathology announced the publication of best practice recommendations for clinical laboratories developing and performing homologous recombination deficiency (HRD) testing ...

The ability of the Geneva homologous recombination deficiency (HRD) test to predict progression-free survival (PFS) in patients with high-grade ovarian cancer treated with poly (ADP-ribose) polymerase ...

Over 20% of high-grade serous ovarian cancer patients have BRCA mutations, and up to 50% exhibit HRD, impacting DNA repair pathways. Global guidelines recommend BRCA and HRD testing, but many eligible ...

Myriad Genetics, Inc. MYGN recently announced a collaboration with GSK plc GSK to advance in the field of genetic testing. The latest development is intended to improve access to homologous ...